It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding the molecular events controlling melanoma progression is of paramount importance for the development of alternative treatment options for this devastating disease. Here we report a mechanism regulated by the oncogenic SOX2-GLI1 transcriptional complex driving melanoma invasion through the induction of the sialyltransferase ST3GAL1. Using in vitro and in vivo studies, we demonstrate that ST3GAL1 drives melanoma metastasis. Silencing of this enzyme suppresses melanoma invasion and significantly reduces the ability of aggressive melanoma cells to enter the blood stream, colonize distal organs, seed and survive in the metastatic environment. Analysis of glycosylated proteins reveals that the receptor tyrosine kinase AXL is a major effector of ST3GAL1 pro-invasive function. ST3GAL1 induces AXL dimerization and activation that, in turn, promotes melanoma invasion. Our data support a key role of the ST3GAL1-AXL axis as driver of melanoma metastasis, and highlight the therapeutic potential of targeting this axis to treat metastatic melanoma.
Understanding the molecular events controlling melanoma progression are necessary to find improved therapeutics. Here, the authors report oncogenic SOX2-GLI1 transcriptional complex to drive melanoma invasion through the induction of the sialyltransferase ST3GAL1, and report ST3GAL1-AXL axis as driver of melanoma metastasis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy
2 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy; University of Siena, Department of Medical Biotechnologies, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641)
3 University of Florence, Department of Clinical and Experimental Medicine, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
4 University of Siena, Department of Biotechnology, Chemistry and Pharmacy, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641)
5 Mayo Clinic, Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
6 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy (GRID:grid.66875.3a); University of Siena, Department of Medical Biotechnologies, Siena, Italy (GRID:grid.9024.f) (ISNI:0000 0004 1757 4641)
7 Mayo Clinic, Department of Radiation Oncology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
8 Mayo Clinic, Rochester, Department of Health Sciences Research, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
9 University of Florence, Department of Neurosciences, Psychology, Drug Research and Child Health, Florence, Italy (GRID:grid.8404.8) (ISNI:0000 0004 1757 2304)
10 University of Padova and Azienda Ospedaliera di Padova, Proteomics Center, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630)
11 University of Padova and Azienda Ospedaliera di Padova, Proteomics Center, Padova, Italy (GRID:grid.411474.3) (ISNI:0000 0004 1760 2630); University of Padova, Department of Biomedical Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470)
12 Mayo Clinic, Department of Dermatology, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
13 Mayo Clinic, Department of Molecular Pharmacology & Experimental Therapeutics, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
14 Core Research Laboratory – Institute for Cancer Research and Prevention (ISPRO), Florence, Italy (GRID:grid.66875.3a)